重组人类促红细胞生成素防治极低出生体重儿贫血的临床观察

目的：探讨重组人类促红细胞生成素（rHuEPO）防治极低出生体重儿贫血的疗效。方法：将42例极低出生体重儿按入院次序分成治疗组21例，对照组21例，治疗组于出生第8天，即予rHuEPO600IU／（kg.w），隔日1次，每周3次，皮下注射，共5周；对照组未予rHuEPO治疗。结果：治疗组较对照组出现贫血率低（19．04％vs61.90%），两组比较有显著性差异（P＜0．01）；两组极低出生体重儿生后血红蛋白、红细胞数、红细胞压积均逐步下降，但治疗组较对照组上述指标下降程度明显减轻，差异有显著性（P＜0．01或0．05）。结论：早期大剂量rHuEPO能够低极低出生体重儿贫血发生率，并能减轻其贫血的程度。

Clinical evaluation of recombinant human erythropoietin in preventing anemia of very low birth weight infants

Objective To evaluate the efficacy of recombinant human erythropoietin (rHuEPO) in preventing anemia of very low birth weight (VLBW) infants. Methods 42 VLBW infants were randomly assigned to the treated group(n=21) and the control group (n=21). The treated group received rHuEPO 600IU/(kg-w)] three times weekly by sub-cutanous injection from 8th day of life. Results The prevalence of anemia in the treated group was abviously lower than that in the control group (19.04% vs 61.90%)(P<0.01). Postnatal decline of hemoglobin(Hb), Red blood cells(RBC).and reticulo-cyte (Ret) were lessened in the treated group and there were significant differenee between the two groups(P<0.01 or 0.05). Conclusion Early administration of high -dose rHuEPO can reduce the prevalence of anemia of VLBW infants and lighten the degree of anemia.